SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with strong financial metrics, including a 13% YoY improvement in adjusted EBITDA and stable customer retention. The AstraZeneca partnership and growth in clinical and biopharma segments are promising, despite conservative guidance. The Q&A reveals strong momentum and optimism for 2026, with significant potential from MSK-ACCESS and biopharma segments. While some details remain confidential, overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Revenue grew 23% year-over-year in Q3 2025, reaching $19.5 million compared to $15.9 million in Q3 2024. This growth was driven by strong business momentum, new customer signings, and expansion in the U.S. market.
U.S. Revenue U.S. revenue grew 30% year-over-year in Q3 2025, driven by new customer signings and increased adoption of SOPHiA DDM applications.
Gross Margin Gross margin was 73.1% on an adjusted basis in Q3 2025, remaining flat year-over-year despite a 40% increase in data processed by the platform. This was achieved through targeted platform improvements that reduced cloud compute and storage costs.
Adjusted EBITDA Adjusted EBITDA improved 13% year-over-year in Q3 2025, excluding the impact of elevated Swiss social charges on stock-based compensation. This improvement reflects strong expense control and natural operating leverage.
Platform Analysis Volume Platform analysis volume was approximately 99,000 in Q3 2025, up 9% from 91,000 in Q3 2024. This growth was supported by new customer implementations and expanded usage of SOPHiA DDM applications.
Core Genomic Customers Core genomic customers totaled 488 as of September 30, 2025, up from 462 in the prior year period. This increase reflects the company's focus on winning larger accounts.
Net Dollar Retention Net dollar retention for Q3 2025 was 108%, with strong performance in Europe, Asia Pacific, and North America, partially offset by a decline in Latin America.
Annualized Revenue Churn Annualized revenue churn remained at approximately 4% in Q3 2025, indicating stable customer retention.
Operating Expenses Operating expenses grew 1% year-over-year in Q3 2025 after adjusting for temporary charges such as Swiss social taxes, foreign exchange impacts, and legal expenses. This reflects strong expense control and targeted investments in sales and marketing.
Cash Burn Total cash burn in Q3 2025 was $13.1 million, up 36.5% year-over-year due to investments in Japan, vendor payments, and increased interest expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MSK-ACCESS: Continued success with the liquid biopsy application, now available globally. Signed over 60 liquid biopsy customers worldwide. Partnered with AstraZeneca for global deployment and announced partnerships with Myriad Genetics and A.D.A.M. Innovations for regulated companion diagnostics in the U.S. and Japan.
SOPHiA DDM Digital Twins: Announced a breakthrough AI-powered research tool that creates virtual representations of patients to simulate outcomes and assist oncologists in treatment decisions. Currently focused on non-cancer applications.
U.S. Market Growth: Revenue grew 30% year-over-year in Q3. Signed major new customers including Geisinger Health System, Baylor Scott & White Health, and Thermo Fisher Lights Labs.
EMEA Growth: Revenue grew 24% year-over-year, with significant contributions from the U.K. (120% growth) and Belgium (70% growth).
Asia Pacific Expansion: Analysis volume grew 35%, with first revenue from Japan coming online through partnership with A.D.A.M. Innovations.
Revenue Growth: Achieved 23% year-over-year revenue growth in Q3, raising 2025 revenue guidance to $75-$77 million.
Operational Efficiency: Maintained gross margin at 73.1% despite a 40% increase in data processed. Improved adjusted EBITDA by 13% year-over-year, excluding Swiss social charges.
Biopharma Partnerships: Signed largest contract in company history with AstraZeneca for breast cancer outcomes. Additional partnership with AstraZeneca for prostate and breast cancer detection using AI algorithms.
Decentralized Testing: Increased demand for in-house testing by hospitals and health systems, driven by operational efficiencies and better patient data utilization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Legal Risks: Guardant Health filed a lawsuit against SOPHiA GENETICS in Europe and the United Kingdom, alleging patent infringement in the MSK-ACCESS application. This has led to increased legal expenses and potential reputational risks.
Currency Exchange Risks: The strengthening of the Swiss franc by 14% since the start of the year has increased payroll and rent expenses in Switzerland when translated into U.S. dollars, negatively impacting operating expenses.
Market and Regional Risks: Latin America continues to experience softness in revenue growth, which could delay the region's contribution to overall company performance.
Operational and Implementation Risks: The complexity of decentralizing liquid biopsy testing, including workflow heterogeneity and the small amount of circulating tumor DNA in blood samples, poses challenges to reliable implementation and scaling.
Financial Risks: Total cash burn increased by 36.5% year-over-year, driven by higher vendor payments, investments, and interest expenses, which could strain financial resources if not managed effectively.
Competitive Pressures: The company faces increasing competition from other players like Illumina, Ultima, MGI, Element, and Roche, which are deploying advanced products that could challenge SOPHiA's market position.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: SOPHiA GENETICS has raised its 2025 revenue guidance to $75 million to $77 million, representing growth of 15% to 18%, up from the previous range of $72 million to $76 million.
Adjusted EBITDA Loss Guidance: The company revised its adjusted EBITDA loss guidance to a range of $39 million to $41 million, compared to $40.2 million in fiscal year 2024. This revision accounts for Swiss social taxes on stock-based compensation and currency impacts.
Future Revenue Growth: The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027.
Market Expansion and Product Growth: SOPHiA GENETICS plans to continue expanding its liquid biopsy application, MSK-ACCESS, and expects it to drive meaningful growth in Q4 2025 and into 2026 as customers complete implementations and ramp up usage.
Operational Investments: The company will make targeted investments in marketing, commercial teams, and implementation teams to support medium-term growth objectives, with a focus on high ROI activities.
Cost Optimization: SOPHiA GENETICS will continue to optimize cloud compute and storage costs, aiming for modest gross margin expansion beyond current levels.
Pipeline and Customer Growth: The company reported a substantial increase in its pipeline, with bookings in the first three quarters of 2025 more than double those of 2024. Average contract value of new customers in Q3 2025 increased by over 180% year-on-year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why does the midpoint of the guidance imply a mid-teens growth for Q4 compared to the 23% growth in Q3?
A:The company has been conservative with its guidance to ensure it can overachieve. Despite the prudence, the business has strong momentum, and there is no change in the key drivers of growth.
Q:How many of the 60 MSK customers are performing analysis or generating revenue, and what is the pipeline for potential customers?
A:About 20% of the 60 customers have started routine operations, though the monthly cadence is still modest. The company expects a significant ramp-up in the next 1-2 quarters, with strong growth anticipated for 2026.
Q:What is Thermo Fisher doing with the product?
A:Thermo Fisher is using the product in one of their laboratories, but details are limited due to confidentiality. It is part of orthogonal studies and work involving other technologies.
Q:What is the outlook for biopharma R&D spending and funding for 2026?
A:The company is optimistic about biopharma spending, citing strong pipelines, hybrid centralized approaches for CDx, and unique capabilities in AI and liquid biopsy. The pipeline is healthy, with active engagement with most top 20 pharma companies.
Q:How did customer onboarding setup times trend in Q3, and were there any macro impacts or concerns about a U.S. government shutdown?
A:Customer onboarding and implementation activities were healthy, with no macro or government shutdown impacts. The company had a record October and expects strong Q4 performance.
Q:What was the contribution of AstraZeneca in Q3, and what is the strength of biopharma excluding AstraZeneca?
A:AstraZeneca's contribution in Q3 was small, with a ramp-up expected in Q4. The biopharma pipeline is strong, with significant deals outside AstraZeneca, though some cannot be disclosed due to confidentiality.
Q:What is the timing and regulatory outlook for companion diagnostics with Myriad Genetics and Genesis Healthcare?
A:The regulatory frameworks differ by region, with Myriad focusing on the U.S. and Genesis on Japan. The company is engaged in several opportunities and expects these tools to be significant drivers in the future.
Q:Will the onboarding of new MSK-ACCESS customers continue each quarter, or will it level off?
A:The onboarding of MSK-ACCESS customers is expected to continue, though not perfectly linear. The existing signed accounts have significant potential, and the company is confident in their contribution to 2026 growth.
Q:What is the current backlog of customers waiting to be implemented?
A:The backlog is at its highest levels, with significant accounts expected to go live in the next few months. The company is optimizing the end-to-end process to improve implementation times.
Q:Can growth in 2026 exceed mid-teens, given the clinical momentum and pharma recovery?
A:The company aims to guide conservatively but is confident in its trajectory. It is focused on achieving historical growth rates and overperforming against expectations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about Thermo Fisher's use of the product, citing confidentiality. Additionally, some significant biopharma deals outside AstraZeneca were not disclosed due to confidentiality.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADAM
AZ
CDx
Digital Twins
ESMO
Japan
SOPHiA application
South
United Kingdom
University
adjustment
agent
approval
biopharma company
biopsy testing
breast prostate
charge share
expand
facility
franc
health system
house testing
oncologist treatment
pathway
payroll rent
project
prostate cancer
share compensation
share price
shelf
stock compensation
table
tax
tumor application
SOPH Transcript
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary indicates positive aspects such as revenue growth, strong net dollar retention, and strategic partnerships. The Q&A section adds confidence in customer onboarding and ASP trends, despite some regional challenges. The company's strategic focus on biopharma and platform expansion, along with optimistic guidance, suggests a favorable market reaction. While cash burn increased, it was due to strategic investments. Overall, the sentiment is positive, with strong growth drivers and strategic partnerships likely supporting a stock price increase.
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call summary and Q&A highlight strong growth prospects, including raised revenue guidance, increased customer base, and strategic investments in high ROI activities. Despite uncertainties in the pharma segment, the company shows balanced growth across sectors and a positive trend in net dollar retention. Cost optimizations and improved cash burn, along with optimistic guidance, contribute to a positive outlook. The market expansion and customer growth further support a positive sentiment, likely leading to a stock price increase in the short term.
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call presents a positive outlook with strong financial metrics, including a 13% YoY improvement in adjusted EBITDA and stable customer retention. The AstraZeneca partnership and growth in clinical and biopharma segments are promising, despite conservative guidance. The Q&A reveals strong momentum and optimism for 2026, with significant potential from MSK-ACCESS and biopharma segments. While some details remain confidential, overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong U.S. market growth, improved gross margins, and significant partnership expansion with AstraZeneca, which is the largest in the company's history. Despite an increase in operating loss, the company's strategic focus on new applications, customer growth, and cost management reflect a positive outlook. The Q&A section reinforces this sentiment with optimistic guidance on product adoption and contract value increases. Although management was conservative about disclosing specific contract sizes, the overall narrative suggests positive momentum, warranting a 'Positive' sentiment rating.
SOPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
